Blood Test To Speed Lung Cancer Diagnosis is Highly Cost Effective, Study Finds

27 January 2020


27th January 2020

A study funded by The National Institute for Health Research (NIHR) SBRI programme and led by Leeds University Academic Unit of Health Economics, supported by the NIHR Leeds In-vitro Diagnostics Co-operative (NIHR Leeds MIC), shows that using a blood test in the cancer risk assessment of indeterminate pulmonary nodules is highly cost-effective and could speed the time to diagnosis.

At a price point of £70, a blood test known as the EarlyCDT Lung test is more effective compared to CT surveillance with an incremental cost-effectiveness ratio (ICER) of less than £2,500 depending on the test accuracy parameters used.

Lung cancer is one of the most prevalent forms of cancer and kills more women than breast and ovarian cancers combined. Five-year survival rates for breast and bowel cancer patients are 86% and 59% respectively. Both of these cancers have screening programmes. Five-year survival for lung cancer, which has no screening programme, is less than 10%.

Oncimmune’s Early-CDT Lung is a simple ELISA blood test that measures seven lung cancer-specific antibodies and ca

n be used for the assessment of malignancy risk in patients with indeterminate pulmonary nodules (IPNs).

Robust and easy to use, it can be run in any laboratory with standard laboratory equipment and more than 160,000 tests have been sold. A ‘kit’ form of the test was CE marked in May 2017 for distribution to laboratories outside the USA.

Dr Helen Radford, Director of Operations, NIHR Leeds MIC, said: “This exciting and important project also included an NHS laboratory validation alongside focus groups with members of the public to understand the patient’s

 perception in early lung cancer screening and how this blood test could help. We look forward to working with Oncimmune in the future.”

Dr Adam M. Hill, CEO, Oncimmune Plc said: “The NIHR Leeds MIC was an excellent delivery partner for this project. Their support in bringing the multidisciplinary teams together from across the University and local NHS Trust enabled us to generate further data in support of our adoption discussions with the NHS.”

Related Themes

Related Team Members

Dr Bethany Shinkins

Associate Director of Methodology and Health Economics Theme Lead